ROLANDO, Barbara
ROLANDO, Barbara
SCIENZA E TECNOLOGIA DEL FARMACO
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer
2023-01-01 Chiara Vigato, Agnese Chiara Pippione, Stefano Sainas, Iole Mannella, Laura Bertarini, Sandra Kovachka, Barbara Rolando, Osman Asghar Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi
Carnosine analogues containing Phenol substructures
2012-01-01 Giorgis M.; Bertinaria M.; Rolando B.; Montanaro G.; Fruttero R.; Gasco A.
Design and synthesis of SWIR emitters for optical imaging
2022-01-01 Federica Blua, Mariangela Boccalon, Barbara Rolando, Roberta Napolitano, Massimo Bertinaria
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives
2012-01-01 M. Bertinaria; M. A. A. G. Shaikh; C. Cena; B. Rolando; L. Lazzarato; R. Fruttero; A. Gasco; G. E. Rovati; C. Buccellati; V. Capra; A. Sala
EFFICIENTLY TARGETING DRUG EFFLUX THROUGH MODULATION OF P-GLYCOPROTEIN ACTIVITY BY SMALL MOLECULES: DESIGN, BIOLOGICAL AND COMPUTATIONAL STUDY.
2019-01-01 Stefano Guglielmo, Marialessandra Contino, Chiara Riganti, Barbara Rolando, Loretta Lazzarato
Evaluation of the targeting ability of folate containing liposomal nitrooxy-doxorubicin.
2015-01-01 Pedrini, I.; Costamagna, F.; Buondonno, I.; Salaroglio, I. C.; Rolando, B.; Chegaev, K.; Fruttero, R.; Riganti, C.; Arpicco, S.
HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER
2023-01-01 Agnese C. Pippione, Stefano Sainas, Chiara Vigato, Iole Mannella, Irene Castellino, Sandra Kovachka, Mariia Iakovleva, Barbara Rolando, Tomasz Wrobel, Osman A. Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco L. Lolli, Donatella Boschi
Identification of 2,3-diaminophenazine and o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan
2003-01-01 GROSA G; B. ROLANDO; MARABELLO D; GERVASIO G
INCAPSULATED NO-GEMCITABINE: GASEOUS SOLUTION FOR MDR PANCREATIC CANCER
2019-01-01 Chegaev, K.; Masetto, F.; Gazzano, E.; Mullappily, N.; Rolando, B.; Donadelli, M.; Arpicco, S.; Riganti, C.; Fruttero, R.
MODIFIED DOXORUBICINS: "GASEOUS APPROACH" TO OVERCOME CARDIOTOXICITY AND MULTIDRUG RESISTANCE
2016-01-01 Chegaev, K.; Rolando, B.; Gazzano, E.; Riganti, C.; Fruttero, R.
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer
2021-01-01 Agnese Chiara Pippione, Zuhal Kilic-Kurt, Stefano Sainas, Iole Mannella, Barbara Rolando, Sandra Kovachka, Francesca Spyrakis, Annamaria Buschini, Serena Montalbano, Simonetta Oliaro Bosso, Marco Lolli, Donatella Boschi
Multitarget antioxidant NO-donor organic nitrates: a novel approach to overcome nitrates tolerance
2022-01-01 Elisabetta Marini, Marta Giorgis, Barbara Rolando, Konstantin Chegaev
Multitarget Drugs: No-Donor Doxorubicins
2015-01-01 Chegaev, Konstantin; Riganti, Chiara; Gazzano, Elena; Rolando, Barbara; Fruttero, Roberta; Gasco, Alberto
Multitarget drugs: NO-donor doxorubicins
2012-01-01 Chegaev K.; Riganti C.; Rolando B.; Federico A.; Fruttero R.; Gasco A.
NEW AKR1C3 INHIBITORS WITH BENZOISOXAZOLE CORE: DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY TO TARGET PROSTATE CANCER
2022-01-01 Pippione Agnese Chiara , Iakovleva, M.; Vottero, C.; Sainas, S; Kilic-Kurt, Z.; Rolando, B; Kovachka, S; Spyrakis, F; Buschini, A.; Montalbano, S.; Oliaro Bosso, S.; Lolli, M.L, Boschi, D.
New class of NO-donor soluble aspirins
2012-01-01 Marini E.; Rolando B.; Lazzarato L.; Joseph S.; Fruttero R.
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer
2022-01-01 Chiara Vigato, Agnese Chiara Pippione, Iole Mannella, Mariia Iakovleva, Stefano Sainas, Simonetta Oliaro Bosso, Barbara Rolando, Sandra Kovachka, Francesca Spyrakis, Marco Lucio Lolli, Donatella Boschi
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer
2021-01-01 Mannella, Iole, Vigato, Chiara, Pasha, Rabia; Pippione Agnese Chiara, Sainas, Stefano, Oliaro Bosso Simonetta; Rolando, Barbara; Kovachka, Sandra, Spyrakis, Francesca; Boschi, Donatella, Lolli. Marco Lucio
NITRIC OXIDE DONOR DOXORUBICINS: A USEFUL STRATEGY TO ADDRESS THE PROBLEM OF MDR IN CANCER THERAPY
2012-01-01 Rolando B.; Riganti C.; Chegaev K.; Fruttero R.; Gasco A.
Nitrooxy-doxorubicin: A New Weapon Against Multidrug Resistance.
2013-01-01 Joanna Kopecka; Chiara Riganti; Barbara Rolando; Ivana Campia; Konstantin Chegaev; Loretta Lazzarato; Antonella Federico; Roberta Fruttero; Dario Ghigo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer | 2023 | Chiara Vigato, Agnese Chiara Pippione, Stefano Sainas, Iole Mannella, Laura Bertarini, Sandra Kovachka, Barbara Rolando, Osman Asghar Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi | |
| Carnosine analogues containing Phenol substructures | 2012 | Giorgis M.; Bertinaria M.; Rolando B.; Montanaro G.; Fruttero R.; Gasco A. | |
| Design and synthesis of SWIR emitters for optical imaging | 2022 | Federica Blua, Mariangela Boccalon, Barbara Rolando, Roberta Napolitano, Massimo Bertinaria | |
| Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives | 2012 | M. Bertinaria; M. A. A. G. Shaikh; C. Cena; B. Rolando; L. Lazzarato; R. Fruttero; A. Gasco; G. E. Rovati; C. Buccellati; V. Capra; A. Sala | |
| EFFICIENTLY TARGETING DRUG EFFLUX THROUGH MODULATION OF P-GLYCOPROTEIN ACTIVITY BY SMALL MOLECULES: DESIGN, BIOLOGICAL AND COMPUTATIONAL STUDY. | 2019 | Stefano Guglielmo, Marialessandra Contino, Chiara Riganti, Barbara Rolando, Loretta Lazzarato | |
| Evaluation of the targeting ability of folate containing liposomal nitrooxy-doxorubicin. | 2015 | Pedrini, I.; Costamagna, F.; Buondonno, I.; Salaroglio, I. C.; Rolando, B.; Chegaev, K.; Fruttero, R.; Riganti, C.; Arpicco, S. | |
| HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER | 2023 | Agnese C. Pippione, Stefano Sainas, Chiara Vigato, Iole Mannella, Irene Castellino, Sandra Kovachka, Mariia Iakovleva, Barbara Rolando, Tomasz Wrobel, Osman A. Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco L. Lolli, Donatella Boschi | |
| Identification of 2,3-diaminophenazine and o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan | 2003 | GROSA G; B. ROLANDO; MARABELLO D; GERVASIO G | |
| INCAPSULATED NO-GEMCITABINE: GASEOUS SOLUTION FOR MDR PANCREATIC CANCER | 2019 | Chegaev, K.; Masetto, F.; Gazzano, E.; Mullappily, N.; Rolando, B.; Donadelli, M.; Arpicco, S.; Riganti, C.; Fruttero, R. | |
| MODIFIED DOXORUBICINS: "GASEOUS APPROACH" TO OVERCOME CARDIOTOXICITY AND MULTIDRUG RESISTANCE | 2016 | Chegaev, K.; Rolando, B.; Gazzano, E.; Riganti, C.; Fruttero, R. | |
| Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer | 2021 | Agnese Chiara Pippione, Zuhal Kilic-Kurt, Stefano Sainas, Iole Mannella, Barbara Rolando, Sandra Kovachka, Francesca Spyrakis, Annamaria Buschini, Serena Montalbano, Simonetta Oliaro Bosso, Marco Lolli, Donatella Boschi | |
| Multitarget antioxidant NO-donor organic nitrates: a novel approach to overcome nitrates tolerance | 2022 | Elisabetta Marini, Marta Giorgis, Barbara Rolando, Konstantin Chegaev | |
| Multitarget Drugs: No-Donor Doxorubicins | 2015 | Chegaev, Konstantin; Riganti, Chiara; Gazzano, Elena; Rolando, Barbara; Fruttero, Roberta; Gasco, Alberto | |
| Multitarget drugs: NO-donor doxorubicins | 2012 | Chegaev K.; Riganti C.; Rolando B.; Federico A.; Fruttero R.; Gasco A. | |
| NEW AKR1C3 INHIBITORS WITH BENZOISOXAZOLE CORE: DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY TO TARGET PROSTATE CANCER | 2022 | Pippione Agnese Chiara , Iakovleva, M.; Vottero, C.; Sainas, S; Kilic-Kurt, Z.; Rolando, B; Kovachka, S; Spyrakis, F; Buschini, A.; Montalbano, S.; Oliaro Bosso, S.; Lolli, M.L, Boschi, D. | |
| New class of NO-donor soluble aspirins | 2012 | Marini E.; Rolando B.; Lazzarato L.; Joseph S.; Fruttero R. | |
| New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer | 2022 | Chiara Vigato, Agnese Chiara Pippione, Iole Mannella, Mariia Iakovleva, Stefano Sainas, Simonetta Oliaro Bosso, Barbara Rolando, Sandra Kovachka, Francesca Spyrakis, Marco Lucio Lolli, Donatella Boschi | |
| New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer | 2021 | Mannella, Iole, Vigato, Chiara, Pasha, Rabia; Pippione Agnese Chiara, Sainas, Stefano, Oliaro Bosso Simonetta; Rolando, Barbara; Kovachka, Sandra, Spyrakis, Francesca; Boschi, Donatella, Lolli. Marco Lucio | |
| NITRIC OXIDE DONOR DOXORUBICINS: A USEFUL STRATEGY TO ADDRESS THE PROBLEM OF MDR IN CANCER THERAPY | 2012 | Rolando B.; Riganti C.; Chegaev K.; Fruttero R.; Gasco A. | |
| Nitrooxy-doxorubicin: A New Weapon Against Multidrug Resistance. | 2013 | Joanna Kopecka; Chiara Riganti; Barbara Rolando; Ivana Campia; Konstantin Chegaev; Loretta Lazzarato; Antonella Federico; Roberta Fruttero; Dario Ghigo |